cemiplimab
Sign in to saveCemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
Medication
- Brand names
- Libtayo
- Drug class
- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
- Active ingredients
- cemiplimab
- Dosage form
- Injection
Sources: openFDA · RxNorm (NLM). Not medical advice.
Clinical Trials
169 registered- PHASE2ACTIVE_NOT_RECRUITINGTesting the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaAlliance for Clinical Trials in Oncology · NCT05694871
- PHASE2RECRUITINGA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)Regeneron Pharmaceuticals · NCT06465329
- PHASE2ACTIVE_NOT_RECRUITINGA Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryRegeneron Pharmaceuticals · NCT06161441
- PHASE1/PHASE2WITHDRAWNBIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell LymphomaAHS Cancer Control Alberta · NCT05538988
- PHASE2COMPLETEDCemiplimab for Secondary AngiosarcomasRadboud University Medical Center · NCT04873375
- PHASE1RECRUITINGA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.OncoNano Medicine, Inc. · NCT06022029
~5 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- History
- References
- External links
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.
Excerpted from Wikipedia’s “cemiplimab” article, available under the CC BY-SA 4.0 licence.